A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)
A Phase 2, Single-masked, Multicentre Study to Evaluate the Safety and Efficacy of 2 Dose Levels of THR-317 for the Treatment of Diabetic Macular Oedema (DME)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Brno, Czechia, 625 00
-
Hradec Kralove, Czechia, 500 05
-
Praha 10, Czechia, 100 34
-
Praha 8, Czechia, 180 00
-
-
-
-
-
Budapest, Hungary, 1083
-
Budapest, Hungary, 1133
-
Debrecen, Hungary, 4032
-
Pecs, Hungary, 7621
-
Szeged, Hungary, 6720
-
-
-
-
-
Bratislava, Slovakia, 826 06
-
Bratislava, Slovakia, 851 07
-
Trenčín, Slovakia, 911 71
-
Zilina, Slovakia, 012 07
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Male or female aged 18 years or older
- Type 1 or type 2 diabetes
- Centre-involved DME with CST ≥ 340µm on Spectralis SD-OCT or ≥ 320µm on non-Spectralis SD OCT, in the study eye
- Reduced vision primarily due to DME, with BCVA between 72 and 23 ETDRS letters read at 4 meters (20/40 and 20/320 Snellen equivalent) in the study eye
- Anti-vascular endothelial growth factor (anti-VEGF) treatment naïve study eye or poor response to prior anti-VEGF treatment in the study eye
- Non-proliferative diabetic retinopathy, or stable proliferative diabetic retinopathy without neovacularisation at the disc
- Written informed consent obtained from the subject prior to screening procedures
Exclusion criteria:
- Concurrent disease in the study eye, other than DME, that could compromise BCVA, require medical or surgical intervention during the study period or could confound interpretation of the results
- Previous treatments / procedures in the study eyes as follows, or their planned use during the THR-317 treatment period for up to 30 days after the last injection: panretinal or focal / grid laser photocoagulation [3 months], anti-VEGF treatment [any time for anti-VEGF naïve subjects; 4 weeks for subjects with a poor response to anti-VEGF treatment], intra-ocular or peri-ocular corticosteroids [4 months], steroid implant [any time], intra-ocular surgery [3 months], vitrectomy [any time]
- Any active ocular / intra-ocular infection or inflammation in either eye
- Aphakic study eye
- Untreated diabetes
- Glycated haemoglobin A (HbA1c) > 12%
- Uncontrolled hypertension in the opinion of the Investigator
- Pregnant or lactating female or female of child-bearing potential not utilising an adequate form of contraception or male of reproductive potential not utilising contraception suggesting lens / zonular instability
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: THR-317 4mg
anti-PlGF recombinant monoclonal antibody, 4mg dose
|
3 intravitreal injections of THR-317 4mg approximately 1 month apart
|
|
Experimental: THR-317 8mg
anti-PlGF recombinant monoclonal antibody, 8mg dose
|
3 intravitreal injections of THR-317 8mg approximately 1 month apart
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of acute (up to the 7-day follow-up visit) ocular (serious) adverse events ([S]AEs) in the study eye, after each injection and across injections per subject
Time Frame: up to the 7-day follow-up visit after each injection
|
up to the 7-day follow-up visit after each injection
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of systemic and ocular (S)AEs up to the 30-day follow-up visit, after each injection and across injections per subject
Time Frame: up to the 30-day follow-up visit after each injection
|
up to the 30-day follow-up visit after each injection
|
|
Incidence of systemic and ocular (S)AEs from first injection up to Day 90 and up to Day 150
Time Frame: From day 0 to day 150
|
From day 0 to day 150
|
|
Proportion of subjects withdrawn from repeat injection and reason for withdrawal
Time Frame: At day 30 and at day 60
|
At day 30 and at day 60
|
|
Proportion of subjects with a loss of ≥ 15, ≥ 10 or ≥ 5 ETDRS letters in BCVA from baseline by study visit
Time Frame: Up to day 150
|
Up to day 150
|
|
Proportion of subjects with an acute loss (up to the 7-day follow-up visit) of ≥ 15, ≥ 10 or ≥ 5 ETDRS letters in BCVA after each injection
Time Frame: Up to 7-day follow-up visit after each injection
|
Up to 7-day follow-up visit after each injection
|
|
Proportion of subjects with a ≥ 15 ETDRS letters gain in BCVA from baseline or ≥ 83 ETDRS letters, by study visit
Time Frame: Up to day 150
|
Up to day 150
|
|
Mean change from baseline in BCVA, by study visit
Time Frame: Up to day 150
|
Up to day 150
|
|
Mean change from baseline in CST, by study visit, based on spectral domain optical coherence tomography (SD-OCT), as assessed by the central reading centre (CRC)
Time Frame: Up to day 150
|
Up to day 150
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clinical Department, ThromboGenics
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Eye Diseases
- Endocrine System Diseases
- Diabetic Angiopathies
- Diabetes Complications
- Diabetes Mellitus
- Retinal Degeneration
- Retinal Diseases
- Macular Degeneration
- Diabetic Retinopathy
- Macular Edema
- Edema
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Antibodies
- Immunoglobulins
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
Other Study ID Numbers
Other Study ID Numbers
- THR-317-001
- 2016-002100-25 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.